Home > Neurology > EAN 2020 > Fremanezumab tolerability in cardiovascular patients with migraine

Fremanezumab tolerability in cardiovascular patients with migraine

In a pooled analysis of 3 phase 3 trials, fremanezumab treatment over 12 weeks was well tolerated, with a low rate of cardiovascular adverse events (AEs) similar to placebo in migraine patients using cardiovascular medication at baseline [1]. There were no new safety signals over 12 weeks of double-blind treatment.

Fremanezumab is a a fully-humanised monoclonal antibody that selectively targets calcitonin gene-related peptide. The 3 trials included were HALO EM, HALO CM, and FOCUS, in which patients were randomised to subcutaneous quarterly or monthly fremanezumab, or placebo over 12 weeks. Overall, 280/2,842 trial participants were receiving cardiovascular medications at baseline, accounting for 9-11% of every treatment group. The most common type of cardiovascular med...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on